Will ORMP's EPS surprises continue in 2024?

**Oramed Pharmaceuticals (ORMP) is likely to experience continued EPS surprises in 2024**, based on several factors: 1. **Historical Performance**: ORMP has shown a history of EPS surprises, with a notable instance in the last reported quarter where the estimated EPS was -$0.03, and the actual EPS was not available. However, the company's stock price decreased by 2.78%, indicating a negative market sentiment. 2. **Industry Trends**: The Pharmaceuticals industry is competitive, with companies like Syros Pharmaceuticals, Inc. (SYRS) and Crinetics Pharmaceuticals, Inc. (CRNX) recently reporting earnings declines. This suggests that ORMP may face similar challenges, potentially impacting its EPS. 3. **Market Analysis**: Analysts have estimated a decline in earnings for Syros Pharmaceuticals, Inc. (SYRS), which was a surprise when the company actually reported a lower loss than expected. This indicates that while surprises can occur, they may not always be in the direction of a positive surprise for ORMP. 4. **Company-Specific Factors**: ORMP's financial performance is likely to be influenced by its drug development pipeline and any regulatory milestones achieved. The company's ability to generate revenue from its products will also be a critical factor in determining the direction of its EPS surprises. In conclusion, while ORMP has the potential to experience EPS surprises in 2024, the direction and frequency of these surprises will depend on a range of factors, including the company's financial performance, industry trends, and market sentiment.